CO6630144A2 - Asociación de inhibidores de la xantina oxidasa y la instatina y su uso - Google Patents

Asociación de inhibidores de la xantina oxidasa y la instatina y su uso

Info

Publication number
CO6630144A2
CO6630144A2 CO12185573A CO12185573A CO6630144A2 CO 6630144 A2 CO6630144 A2 CO 6630144A2 CO 12185573 A CO12185573 A CO 12185573A CO 12185573 A CO12185573 A CO 12185573A CO 6630144 A2 CO6630144 A2 CO 6630144A2
Authority
CO
Colombia
Prior art keywords
association
xanthine oxidase
inhibitors
instatin
namely
Prior art date
Application number
CO12185573A
Other languages
English (en)
Inventor
Francesco Melani
Sandro Giuliani
Carlos Alberto Maggi
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42753376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6630144(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of CO6630144A2 publication Critical patent/CO6630144A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a la asociación de principios activos, a saber de un inhibidor de la xantina oxidasa con uno o más inhibidores de la HMG CoA reductasa, composiciones farmacéuticas que comprende dicho principio activo, para uso en el tratamiento terapéutico humano o veterinario, y métodos para su preparación.
CO12185573A 2010-05-10 2012-10-19 Asociación de inhibidores de la xantina oxidasa y la instatina y su uso CO6630144A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000231A IT1400310B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e statine e loro uso.

Publications (1)

Publication Number Publication Date
CO6630144A2 true CO6630144A2 (es) 2013-03-01

Family

ID=42753376

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12185573A CO6630144A2 (es) 2010-05-10 2012-10-19 Asociación de inhibidores de la xantina oxidasa y la instatina y su uso

Country Status (23)

Country Link
US (1) US20130116291A1 (es)
EP (1) EP2568981A1 (es)
JP (1) JP2013526499A (es)
KR (1) KR20130079427A (es)
CN (1) CN103025329A (es)
AR (1) AR081375A1 (es)
AU (1) AU2011252193A1 (es)
BR (1) BR112012028892A2 (es)
CA (1) CA2798707A1 (es)
CL (1) CL2012003033A1 (es)
CO (1) CO6630144A2 (es)
CR (1) CR20120618A (es)
EA (1) EA201201529A1 (es)
IL (1) IL222926A0 (es)
IT (1) IT1400310B1 (es)
MA (1) MA34232B1 (es)
MX (1) MX2012013052A (es)
NZ (1) NZ603397A (es)
PE (1) PE20130811A1 (es)
SG (1) SG185445A1 (es)
TW (1) TW201206430A (es)
WO (1) WO2011141387A1 (es)
ZA (1) ZA201209294B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112370473A (zh) * 2020-12-04 2021-02-19 首都医科大学附属北京朝阳医院 他汀组合物及其在制备治疗高尿酸血症药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
AU645867B2 (en) 1990-11-30 1994-01-27 Teijin Pharma Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
EP1020454B2 (en) 1998-06-19 2013-01-23 Teijin Pharma Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
JP5242393B2 (ja) 2005-08-03 2013-07-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド 高血圧症の治療方法
WO2007044910A1 (en) * 2005-10-13 2007-04-19 Duke University Compositions for the treatment and prevention of heart disease and methods of using same
CA2630639A1 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
KR20160031040A (ko) 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법

Also Published As

Publication number Publication date
IL222926A0 (en) 2012-12-31
JP2013526499A (ja) 2013-06-24
PE20130811A1 (es) 2013-08-08
SG185445A1 (en) 2012-12-28
NZ603397A (en) 2014-03-28
AU2011252193A1 (en) 2012-11-29
MA34232B1 (fr) 2013-05-02
EA201201529A1 (ru) 2013-04-30
US20130116291A1 (en) 2013-05-09
CL2012003033A1 (es) 2013-06-21
ITRM20100231A1 (it) 2011-11-11
IT1400310B1 (it) 2013-05-24
MX2012013052A (es) 2013-07-03
AR081375A1 (es) 2012-08-29
BR112012028892A2 (pt) 2016-07-26
KR20130079427A (ko) 2013-07-10
WO2011141387A1 (en) 2011-11-17
CR20120618A (es) 2014-03-21
CA2798707A1 (en) 2011-11-17
EP2568981A1 (en) 2013-03-20
CN103025329A (zh) 2013-04-03
TW201206430A (en) 2012-02-16
ZA201209294B (en) 2013-08-28

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2012001757A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas.
GB201014391D0 (en) Drug composition and its use in therapy
TR201004464A2 (tr) Kemik erimesi için formülasyon.
UY33663A (es) Derivados amínicos para el tratamiento de trastornos proliferativos de la piel
CR20150044A (es) Formulación transdérmica que contiene inhibidores de cox
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
BR112012021445B8 (pt) formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade
ECSP12012332A (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
CO6630144A2 (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
BR112013004714A2 (pt) "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso
UY31057A1 (es) Formulaciones de aminoacido n-halogenado que contiene acido alifatico
AR116040A2 (es) Sal tosilato para-toluensulfonato de 4-(6-cloro-3-metil-4,10-dihidro-3h-2,3,4,9-tetraazabenzo[f]azulen-9-carbonil)-2-fluoro-bencilamida del ácido ciclopropancarboxílico
CL2009001327A1 (es) Compuestos heterociclo derivados de 3-oxoisoindolin-1-carboxamida; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento del dolor.
CL2010000899A1 (es) N1-bencil-n8-hidroxi octanodiamida; composicion farmaceutica que comprende a dicho compuesto; combinacion farmaceutica que comprende a dicho compuesto; y su uso en el tratamiento de tumores.(divisional de la solicitud 1247-04).

Legal Events

Date Code Title Description
FC Application refused